iBio (IBIO) Short term Debt (2023 - 2025)
iBio (IBIO) posted quarterly Short term Debt of $16000.0 for Q3 2025, down 91.21% year-over-year from $182000.0 in Q3 2024, and down 75.0% quarter-over-quarter from $64000.0 in Q2 2025.
iBio (IBIO) Short term Debt (2023 - 2025) Analysis & Trends
iBio (IBIO) has reported Short term Debt for 3 consecutive years, with $16000.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Short term Debt fell 91.21% year-over-year to $16000.0; the TTM figure through Sep 2025 stood at $16000.0 (down 91.21% YoY), while the FY2025 annual figure was $64000.0, down 64.04% from the prior year.
- Short term Debt retreated to $16000.0 in Q3 2025 per IBIO's latest filing, from $64000.0 in the prior quarter.
- Across five years, Short term Debt topped out at $182000.0 in Q3 2024 and bottomed at $16000.0 in Q3 2025.
- Historically, Short term Debt has averaged $123571.4 across 3 years, with a median of $155000.0 in 2024.
- Annual changes were most pronounced in 2024 — Short term Debt gained 11.25% — and 2025, when it plunged 91.21%.
- iBio's Short term Debt stood at $160000.0 in 2023, then slipped by 3.12% to $155000.0 in 2024, then slumped by 89.68% to $16000.0 in 2025.
- Business Quant data shows IBIO's Short term Debt at $16000.0 in Q3 2025, $64000.0 in Q2 2025, and $110000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | iBio | 175.21 Mn | 175.21 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 16,000.00 |
| Jun 30, 2025 | 64,000.00 |
| Mar 31, 2025 | 110,000.00 |
| Dec 31, 2024 | 155,000.00 |
| Sep 30, 2024 | 182,000.00 |
| Jun 30, 2024 | 178,000.00 |
| Jun 30, 2023 | 160,000.00 |